F001 Future of Dermatology: Dermatology Beyond 2040
DESCRIPTION
This year, the Future of Dermatology Symposium turns its attention to the long horizon. What will the dermatology visit of 2040 look like? Who—or what—will perform the skin exam? How will imaging, artificial intelligence, ambient documentation, and decentralized diagnostics restructure the clinic, the encounter, and the workforce? The session will pair forward-looking lectures with abstract presentations that stress-test these questions against real data and real technology.
We are pleased to feature Allen Halpern, MD, on the next generation of imaging devices entering the clinic room, and Eugene Semenov, MD, MA, on the integration of artificial intelligence into the dermatology office. Their talks will frame the abstract session, in which our expert panel—spanning therapeutics, diagnostics, molecular technologies, AI, telemedicine, imaging, and digital health—will select the most original and consequential submissions for presentation.
This session is not certified for AMA PRA Category 1 CME Credit.
LEARNING OBJECTIVES
Examine how imaging, artificial intelligence, and ambient clinical technologies are likely to reshape the structure of the visit, the role of the dermatologist, and the patient experience over the next 15 years.
Develop a critical framework for distinguishing transformative innovations from incremental ones, with attention to validation, equity, workflow integration, and regulatory readiness.
Through featured lectures and selected abstracts, identify the translational pathways by which current discoveries in imaging, AI, and digital health are moving toward routine clinical use.
SCHEDULE
1:00 PM
Beyond the Dermatoscope, Vectra and RCM...point-of-care derm devices in 2040
Allan C. Halpern, MD, FAAD
1:40 PM
Beyond Open Evidence, ChatGPT and Claude...AI at the bedside
Yevgeniy Semenov, MD, MS, FAAD
2:20 PM
Panel Discussion and Town Hall Q/A
3:00 PM
Moxidectin for scabies: dose confirmation in a Phase 2, placebo controlled, randomized efficacy and safety study of single oral doses in adults with scabies
Vidya Uprety
3:15 PM
ENV-294, a First-in-Class Oral Small Molecule, Demonstrates Favorable Safety and Robust Efficacy in Moderate-to-Severe Atopic Dermatitis: Results from a Phase1b Open-Label Study
Jonathan I. Silverberg, MD, PhD, MPH, FAAD
3:30 PM
Dermatologist-Performed Ultrasound for Regional Lymph Node Surveillance in High-Stage Cutaneous Squamous Cell Carcinoma: A Prospective Diagnostic Accuracy Study
Nina Ran, MD, MS, FAAD
3:45 PM
Rapid, Dose-Dependent Reduction of Plasma Protoporphyrin IX with PORT-77 in Adults with Erythropoietic Protoporphyria: Results from a Phase 2a Study
Pete Schmidt
4:00 PM
Deep Learning Analysis of Standardized Reflectance Confocal Microscopy Cube Mosaics for Melanoma Diagnosis and Breslow Depth Prediction
Nicholas David Gulati, MD, PhD, FAAD
4:15 PM
A One-Stop-Shop Approach to Low-Risk Basal Cell Carcinoma: Long-Term Outcomes of RCM-OCT–Guided Er:YAG Laser Ablation
Noa Kremer, MD
DIRECTOR
Hensin Tsao, MD, PhD, FAAD
CO-DIRECTORS
Lilit Garibyan, PhD, MD, FAAD
Harvard Medical School & Wellman Center/Mass General Hospital
Allan C. Halpern, MD, FAAD
Memorial Sloan Kettering Cancer Center
Martina J. Porter, MD, FAAD
Beth Israel Deaconess Medical Center & Harvard Medical School
Bobby Y. Reddy, MD, FAAD
Yevgeniy Semenov, MD, MS, FAAD
Sandy Sharon Tsao, MD, FAAD
SPEAKERS
Nicholas David Gulati, MD, PhD, FAAD
Noa Kremer, MD
Nina Ran, MD, MS, FAAD
Brigham and Women's Hospital
Pete Schmidt
Portal Therapeutics (a GondolaBio affiliate)/Stanford University
Jonathan I. Silverberg, MD, PhD, MPH, FAAD
Vidya Uprety
Medicines Development for Global Health
HANDOUTS
DISCLOSURES
Lilit Garibyan, PhD, MD, FAAD
Absci – Consultant (1099 relationship)(Honoraria); Annecy Bio – Board of Directors(Stock); Brixton Biosciences – Consultant(Fees), Stockholder(Stock); Clarity Cosmetics, Inc. – Stockholder Private Company(No Compensation Received); EyeCool – Stockholder(Stock); Matilda Venture Studio – Board of Directors(Stock);
Nicholas David Gulati, MD, PhD, FAAD
Almirall – Advisory Board(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Daiichi Sankyo – Advisory Board(Honoraria); Veradermics – Advisory Board(Honoraria);
Allan C. Halpern, MD, FAAD
Canfield Scientific, Inc. – Consultant(Other Financial Benefit); SpotDoc – Founder(Other Financial Benefit);
Noa Kremer, MD
No financial relationships exist with ineligible companies.
Martina J. Porter, MD, FAAD
AbbVie – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding), Other(Residency/Fellowship Program Funding); Almirall – Consultant (1099 relationship)(Fees); AnaptysBio – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Avalo Therapeutics Inc – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Bayer – Investigator(Grants/Research Funding); Beth Israel Deaconess Medical Center – Other(Patent royalties or other compensation for Intellectual Property Rights); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Citryll – Advisory Board(Fees); Corvus Pharmaceuticals – Consultant (1099 relationship)(Fees); Eli Lilly – Consultant (1099 relationship)(No Compensation Received); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Consultant(Fees); Merck – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Moonlake – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Consultant(Fees), Investigator(Grants/Research Funding); Oasis Pharmaceuticals – Investigator(Grants/Research Funding); Oruka Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Prometheus Laboratories, Inc. – Investigator(Grants/Research Funding); Propeller Bio – Consultant (1099 relationship)(Fees); Regeneron – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Spyre Therapeutics – Consultant (1099 relationship)(Fees); Trifecta Clinical – Consultant(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Ventyx Biosciences – Investigator(Grants/Research Funding); Zura Bio – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Nina Ran, MD, MS, FAAD
Chronicle Medical Software – Consultant (1099 relationship)(Fees);
Bobby Y. Reddy, MD, FAAD
Pi Health – Employee (w-2 relationship)(Salary);
Pete Schmidt
No financial relationships exist with ineligible companies.
Yevgeniy Semenov, MD, MS, FAAD
Alterome Therapeutics – Consultant (1099 relationship)(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Bristol Myers Squibb – Consultant (1099 relationship)(Honoraria); Galderma – Advisory Board(Honoraria); Journal of the American Academy of Dermatology – Other(Salary); Pfizer Inc. – Consultant (1099 relationship)(Honoraria); Pyxis Oncology – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria);
Jonathan I. Silverberg, MD, PhD, MPH, FAAD
AbbVie – Consultant(Honoraria), Speaker(Honoraria); Aldena Therapeutics – Advisory Board(Fees); Amgen – Consultant(Fees); Apollo Therapeutics Ltd – Consultant (1099 relationship)(Fees); Arcutis, Inc. – Consultant(Fees), Speaker(Fees); Attovia Therapeutics – Advisory Board(Fees); Castle Biosciences – Consultant(Fees); Connect Biopharma LLC – Consultant(Fees); Corevitas – Advisory Board(Honoraria); Eli Lilly and Company – Consultant(Honoraria), Speaker(Fees); Enveda Biosciences – Consultant (1099 relationship)(Fees); Galderma – Speaker(Fees); Galderma Research & Development, LLC – Consultant(Honoraria); GlaxoSmithKline – Consultant(Honoraria), Investigator(No Compensation Received); Imagene Bio – Consultant (1099 relationship)(Fees); Imagene Biopharmaceuticals – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Honoraria); Infimmune – Advisory Board(Fees); Leo Pharma Inc – Advisory Board(Honoraria); Leo Pharma Inc. – Investigator(Honoraria); Maui Derm – Speaker(Fees); Nektar Therapeutics – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees); Organon – Speaker(Fees); Pfizer Inc. – Advisory Board(Honoraria), Consultant(Honoraria), Speaker(Fees); Regeneron – Consultant(Honoraria), Investigator(No Compensation Received), Speaker(Honoraria); Sanofi – Consultant(Grants/Research Funding); Sanofi Genzyme – Speaker(Honoraria); Shaperon – Consultant(Fees); UCB – Consultant (1099 relationship)(Fees); UpToDate – Other(Fees);
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria);
Sandy Sharon Tsao, MD, FAAD
Beiersdorf, Inc. – Consultant (1099 relationship)(Honoraria); Epiphany Dermatology – Advisory Board(Stock); WorldCare Clinical LLC – Consultant (1099 relationship)(Honoraria);
Vidya Uprety
No financial relationships exist with ineligible companies.